Naphthenic amino alkoxy substituted aryl pyrone compound and application thereof

CN119095835APending Publication Date: 2024-12-06SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380018423.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-28
Filing Date
2023-01-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing antiviral drugs are ineffective in treating viral infections such as parainfluenza virus, respiratory syncytial virus, and coronavirus, and their safety needs to be improved. In particular, there is a lack of effective drugs for novel coronavirus pneumonia.

Method used

Develop a cycloalkylaminoalkoxy-substituted arylpyrone compound and its pharmaceutically acceptable salts, solvates, optically pure isomers or stereoisomers for the preparation of pharmaceutical compositions, using It is used as an ACE-2 receptor antagonist or inflammatory cytokine inhibitor to improve or reverse diseases caused by viral infections.

Benefits of technology

This compound has been shown in experiments to have excellent effects on diseases caused by multiple viral infections, especially in the treatment of pneumonia in mouse models of influenza virus and coronavirus infection, which significantly reduces the lung index and has strong efficacy and safety. Improve the shortcomings of existing drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095835A_ABST
    Figure CN119095835A_ABST
Patent Text Reader

Abstract

The invention discloses a novel compound as shown in a general formula I, pharmaceutically acceptable salts and solvates of the novel compound, stereoisomers comprising mixtures of the novel compound in various proportions and pharmaceutical compositions containing the novel compound. R1a, R1b, R1c, R2, R3a, R3b, R4a, R4b, R5, R6, X1, X2, X3, A ring and the like have meanings given in the specification. The invention also relates to a preparation method of the compound, and also relates to application of the pharmaceutically acceptable salt, solvate and stereoisomer of the compound in various proportions, especially application in preparation of antiviral drugs. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Cycloalkylaminoalkoxy substituted arylpyrone compound and use thereof Technical Field

[0001] The present invention relates to a novel compound and its pharmaceutically acceptable salts, solvates, stereoisomers including mixtures in various ratios, and pharmaceutical compositions containing the compound. The present invention also relates to the use of the compound and its pharmaceutically acceptable salts, solvates, stereoisomers including mixtures in various ratios, particularly in the preparation of antiviral drugs. Background Art

[0002] A series of antiviral drugs have been developed in this field, such as baloxavir marboxil, peramivir, laninamivir octanoate, oseltamivir, oseltamivir phosphate, zanamivir, rimantadine, and amantadine, which are drugs targeting influenza viruses. However, there are no effective drugs for respiratory viruses such as parainfluenza virus, respiratory syncytial virus, adenovirus, and coronavirus, requiring the use of broad-spectrum antiviral drugs such as ribavirin or interferon. Meanwhile, drugs such as lopinavir / ritonavir, chloroquine phosphate, arbidol, darunavir, hydroxychloroquine, favipiravir, and remdesivir are commonly used for novel coronavirus pneumonia. The above-mentioned antiviral drugs still have many deficiencies in therapeutic efficacy and safety of use. Therefore, the field still needs to develop new antiviral therapeutic drugs.

[0003] Summary of the Invention

[0004] The object of the present invention is to provide an isoflavone derivative and a pharmaceutically acceptable salt thereof.

[0005] The first aspect of the present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt, solvate, optically pure isomer, stereoisomer or mixture thereof,

[0006] wherein X1 and X2 are each independently selected from the group consisting of O and NR7; wherein R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, cycloalkyl, and substituted cycloalkyl;

[0007] X3 is selected from the following group: O, NR8; wherein, R8 is selected from the following group: hydrogen, alkyl;

[0008] R 1a 、R 1b 、R 1c Each independently selected from the group consisting of hydrogen, hydroxy, and alkoxy;

[0009] R2 is selected from the group consisting of substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

[0010] R 3a 、R 3b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen;

[0011] R 4a 、R 4b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen;

[0012] R5 is selected from the group consisting of hydrogen or alkoxy;

[0013] R6 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C2-C6 acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted carbamoyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; wherein R7 is selected from the group consisting of C2-C6 acyl, C2-C6 amide, aryl, heteroaryl, cycloalkyl, heterocyclyl, NR8COR9; wherein R8 is selected from the group consisting of hydrogen, alkyl; and R9 is selected from the group consisting of alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl.

[0014] Ring A is a substituted or unsubstituted cycloalkyl group;

[0015] n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0016] Wherein, each substitution refers to the replacement of hydrogen atoms on the group by one or more substituents selected from the group consisting of cyano, halogen, alkyl, hydroxy, alkoxy, alkenyl, alkynyl, aryl, and heteroaryl;

[0017] Furthermore, the compound of formula I does not include

[0018] In the above formulas, unless otherwise specified, the alkyl group is a C1-C6 alkyl group, and the aryl group is a C6-C 10The aryl group is a C3-C8 cycloalkyl group, the alkoxy group is a C1-C6 alkoxy group, the alkenyl group is a C2-C6 alkenyl group, the alkynyl group is a C2-C6 alkynyl group, and the heteroaryl group is a 5-12 membered (preferably 5-7 membered) heteroaryl group.

[0019] In another preferred embodiment, X1 is O; and / or

[0020] X2 is O.

[0021] In another preferred embodiment, the R7 is selected from the following group: hydrogen and alkyl.

[0022] In another preferred embodiment, X3 is O.

[0023] In another preferred embodiment, R 1a 、R 1b 、R 1c are each independently selected from hydrogen.

[0024] In another preferred embodiment, R2 is a substituted or unsubstituted aryl group, preferably a substituted or unsubstituted phenyl group.

[0025] In another preferred embodiment, R 3a 、R 3b Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, and halogen.

[0026] In another preferred embodiment, R 4a 、R 4b Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, and halogen.

[0027] In another preferred embodiment, R5 is selected from hydrogen or C1-C4 alkoxy.

[0028] In another preferred embodiment, R6 is selected from the following groups: hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted C2-C6 acyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; R7 is selected from the following group: C2-C6 acyl, C2-C6 amide, aryl NR8COR9, and R8 is selected from the following group: hydrogen, alkyl; R9 is selected from the following group: alkyl, aryl.

[0029] In another preferred embodiment, ring A is a substituted or unsubstituted C3-C7 cycloalkyl group, preferably a C3-C6 cycloalkyl group.

[0030] In another preferred embodiment, n is 1, 2, 3 or 4.

[0031] In another preferred embodiment, the R6 is selected from the following group: hydrogen, substituted or unsubstituted alkyl.

[0032] In another preferred embodiment, said R6 is selected from the following group: hydrogen, unsubstituted alkyl.

[0033] In another preferred embodiment, the compound of formula I has the structure shown in formula II,

[0034] Among them, R 9a 、R 9b 、R 9c Each is independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C 10 Aryl, 5-12 membered heteroaryl;

[0035] R 10a 、R 10b 、R 10c 、R 10d 、R 10e Each is independently selected from the group consisting of hydrogen, hydroxy, C1-C6 alkoxy, halogen, and cyano;

[0036] m is 1, 2, 3, 4 or 5.

[0037] In another preferred embodiment, the compound of formula II is selected from the following group:

[0038] In another preferred embodiment, the compound of formula I has the structure shown in formula III,

[0039] R 11a 、R 11b 、R 11c Each is independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C 10 Aryl, 5-12 membered heteroaryl;

[0040] R 12 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C2-C6 acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted carbamoyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; wherein R7 is selected from the group consisting of C2-C6 acyl, C2-C6 amide, aryl, heteroaryl, cycloalkyl, heterocyclyl, NR8COR9; wherein R8 is selected from the group consisting of hydrogen, alkyl; and R9 is selected from the group consisting of alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl.

[0041] R13a 、R 13b 、R 13c 、R 13d 、R 13e Each is independently selected from the group consisting of hydrogen, hydroxy, alkoxy, halogen, and cyano.

[0042] In another preferred embodiment, the compound of formula III is selected from the following group:

[0043] The second aspect of the present invention provides a pharmaceutical composition, which comprises the compound described in the first aspect, or a pharmaceutically acceptable salt, solvate, optically pure isomer or stereoisomer thereof; and a pharmaceutically acceptable carrier.

[0044] The third aspect of the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, solvate, optically pure isomer, stereoisomer or mixture thereof, and use of the pharmaceutical composition described in the second aspect of the present invention, wherein the use is for preparing a pharmaceutical composition;

[0045] X1 and X2 are each independently selected from the group consisting of O and NR7; wherein R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, cycloalkyl, and substituted cycloalkyl;

[0046] X3 is selected from the following group: O, NR8; wherein, R8 is selected from the following group: hydrogen, alkyl;

[0047] R 1a 、R 1b 、R 1c Each independently selected from the group consisting of hydrogen, hydroxy, and alkoxy;

[0048] R2 is selected from the group consisting of substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

[0049] R 3a 、R 3b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen;

[0050] R 4a 、R 4b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen;

[0051] R5 is selected from the group consisting of hydrogen or alkoxy;

[0052] R6 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C2-C6 acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted carbamoyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; wherein R7 is selected from the group consisting of C2-C6 acyl, C2-C6 amide, aryl, heteroaryl, cycloalkyl, heterocyclyl, NR8COR9; wherein R8 is selected from the group consisting of hydrogen, alkyl; and R9 is selected from the group consisting of alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl.

[0053] Ring A is a substituted or unsubstituted cycloalkyl group;

[0054] n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0055] Wherein, each substitution refers to the replacement of hydrogen atoms on the group by one or more substituents selected from the group consisting of cyano, halogen, alkyl, hydroxy, alkoxy, alkenyl, alkynyl, aryl, and heteroaryl;

[0056] And the pharmaceutical composition is used for a purpose selected from the following group:

[0057] (1) Improve, alleviate or reverse diseases or symptoms caused by viral infection;

[0058] (2) As a SARS-Cov-2 virus ACE-2 receptor antagonist;

[0059] (3) As an inhibitor of inflammatory cytokines after infection.

[0060] In another preferred embodiment, the virus is selected from the following group: influenza virus, respiratory syncytial virus, coronavirus (such as SARS-COV-2 virus), and parainfluenza virus.

[0061] In another preferred embodiment, the infection is a viral infection.

[0062] In another preferred embodiment, the virus is selected from the following group: influenza virus, respiratory syncytial virus, coronavirus (such as SARS-COV-2 virus), and parainfluenza virus.

[0063] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 shows a line graph of the efficacy test results of compound 4 against the new coronavirus.

[0065] FIG2 is a cell membrane chromatogram of the compound of the present invention.

[0066] Figure 3 shows the calcium imaging results of compound 4 in ACE2-293T cells.

[0067] FIG4 is a bar graph showing the effect of compound 4 on the INF-β content in lung tissue of a pneumonia model of mice infected with influenza virus FM1.

[0068] FIG5 is a bar graph showing the effect of compound 4 on the TNF-α content in lung tissue of a pneumonia model of mice infected with influenza virus FM1.

[0069] Figure 6 shows a bar graph showing the effect of compound 4 on the IL-1 content in lung tissue of a mouse pneumonia model infected with human coronavirus 229E.

[0070] Figure 7 shows a bar graph showing the effect of compound 4 on the IL-10 content in lung tissue of a mouse pneumonia model infected with human coronavirus 229E. DETAILED DESCRIPTION

[0071] After extensive and in-depth research, the inventors unexpectedly discovered that the compounds of the present invention have excellent effects in treating diseases caused by various viral infections. Consequently, they conducted comparative experiments comparing the compounds of the present invention with various known antiviral drugs, and thus completed the present invention.

[0072] definition

[0073] The following are definitions of terms used in this specification. Unless otherwise indicated, the initial definitions of groups or terms provided herein apply to the groups or terms used in this specification alone or as part of other groups.

[0074] The term "substituted" refers to any substituent mentioned in the present specification, including but not limited to halogen, nitro, cyano, carboxyl, oxo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, hydroxy, alkoxy, aryloxy, alkanoyloxy, aroyloxy, amino, alkanoylamino, aroylamino, arylalkylacylamino, heteroarylalkylacylamino, aminoalkylacylamino, alkylaminoalkylacyl alkylamino, arylamino, arylalkylamino, disubstituted amines (wherein the two amino substituents are selected from alkyl, aryl or arylalkyl), alkanoyl, substituted alkanoyl, aroyl, heteroaroyl, carboxyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, arylalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, carbamoyl, substituted carbamoyl, substituted alkylcarbamoyl, amide, substituted amide, sulfonamido, substituted sulfonamido.

[0075] The term "halogen" or "halo" refers to fluorine, chlorine, bromine, or iodine.

[0076] The term "alkyl" refers to a straight or branched unsubstituted hydrocarbon group having 1 to 20 carbon atoms, preferably 1 to 7 carbon atoms. Examples of "alkyl" include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, and the like.

[0077] The term "substituted alkyl" refers to an alkyl group substituted with one to four substituents, such as halogen, nitro, cyano, carboxyl, oxo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, hydroxy, alkoxy, aryloxy, alkanoyloxy, aroyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amines (wherein both amino substituents are selected from alkyl, aryl or arylalkyl), alkanoyl, substituted alkanoyl, alkoxycarbonyl, arylalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, carbamoyl, substituted carbamoyl, amide, substituted amide, sulfonamido, substituted sulfonamido.

[0078] The term "alkenyl" refers to a straight or branched chain hydrocarbon group having 2 to 20 carbon atoms, preferably 2 to 15 carbon atoms, most preferably 2 to 8 carbon atoms, and having 1 to 4 double bonds.

[0079] The term "substituted alkenyl" refers to alkenyl groups substituted with 1-2 substituents, such as halogen, nitro, cyano, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, alkanoyloxy, aroyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amine (wherein the two amino substituents are selected from alkyl, aryl or arylalkyl).

[0080] The term "alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 20 carbon atoms, preferably 2 to 15 carbon atoms, most preferably 2 to 8 carbon atoms, and having 1 to 4 triple bonds.

[0081] The term "substituted alkynyl" refers to alkynyl groups substituted with substituents such as halogen, nitro, cyano, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, alkoxy, aryloxy, alkanoyloxy, aroyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amines (wherein the two amino substituents are selected from alkyl, aryl or arylalkyl).

[0082] The term "aryl" refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6-12 carbon atoms in the ring portion. Aryl includes bicyclic groups that include rings fused to a saturated or partially unsaturated aromatic ring, or an aromatic carbocyclic or heterocyclic ring. Typical aryl groups include, but are not limited to, the following groups: benzene, naphthalene, anthracene, biphenyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and the like.

[0083] The term "substituted aryl" refers to an aryl group substituted with 1 to 4 substituents, such as halogen, halogen, nitro, cyano, ureido, carboxyl, trifluoromethoxy, trifluoromethyl, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, hydroxy, alkoxy, aryloxy, alkanoyloxy, aroyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amine (wherein both amino substituents are selected from alkyl, aryl or arylalkyl), alkanoyl, substituted alkanoyl, alkoxycarbonyl, arylalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, carbamoyl, substituted carbamoyl, amide, substituted amide, sulfonamido, substituted sulfonamido.

[0084] The term "cycloalkyl" refers to a non-aromatic, saturated or partially unsaturated cyclic hydrocarbon group, which can be arbitrarily substituted with one or more substituents described herein, and which has 3-30 carbon atoms to form a monocyclic ring, or 7-12 carbon atoms to form a bicyclic ring. Examples of monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, cycloheptyl, and cyclooctyl. Exemplary bridged bicyclic cycloalkyls include, but are not limited to, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane.

[0085] The terms "heterocycle", "heterocyclic" and "heterocyclyl" refer to an optionally substituted, fully saturated or unsaturated, aromatic or non-aromatic ring group, for example, a 4-7 membered monocyclic ring, a 7-11 membered bicyclic ring or a 10-15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclyl group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms. The "heterocyclyl" may be arbitrarily substituted with one or more substituents described herein. Examples of "heterocyclyl" include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholino, thiomorpholino, piperazinyl, homopiperazinyl, glycidyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, N-pyridylurea, pyrimidinone and 1,1-dioxo-thiomorpholinyl.

[0086] The term "heteroaryl" refers to a monovalent aromatic group having 5-, 6-, 7-, 8-, 9-, or 10-membered rings and includes fused systems of 5-20 atoms, containing one or more heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur, and optionally substituted with one or more substituents described herein. Examples of "heteroaryl" include, but are not limited to, pyridyl, imidazolyl, imidazopyridyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, thiazolyl, quinolinyl, indolyl, and the like.

[0087] The term "oxo" represents a divalent radical =0.

[0088] The term "carbamoyl" refers to a -OC(=O)NH2 group.

[0089] The term "amide" refers to a -C(=O)NH2 group.

[0090] The term "sulfonamido" refers to the -SO2NH2 group.

[0091] The terms "substituted carbamoyl", "substituted amide" and "substituted sulfonamide" refer to amides, sulfonamides or carbamates, respectively, in which at least one hydrogen atom is replaced by a group selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl and substituted heterocyclyl.

[0092] The term "acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the invention. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, acid sulfate, isonicotinate, lactate, salicylate, acid citrate, succinate, maleate, fumarate, gluconate, formate, mesylate, and pamoate. An "acceptable salt" may involve the inclusion of another molecule, such as maleate or other counterions. Counterions stabilize the charge in the parent compound. An "acceptable salt" may have more than one charged atom, and multiple charged atoms may have multiple counterions.

[0093] If the compound of the present invention is a base, the desired "acceptable salt" can be prepared by a suitable method, for example, by treating the free base with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; or with an organic acid such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, salicylic acid, a pyranosidic acid such as glucuronic acid or galacturonic acid, an α-hydroxy acid such as citric acid or tartaric acid, an amino acid such as glutamic acid, an aromatic acid such as benzoic acid or cinnamic acid, a sulfonic acid such as methanesulfonic acid or p-toluenesulfonic acid.

[0094] If the compound of the present invention is an acid, the desired "acceptable salt" can be prepared by a suitable method, for example, by treating the free acid with an inorganic base or an organic base such as an amine, an alkali metal hydroxide or an alkaline earth metal hydroxide. Illustrative examples of suitable salts include, but are not limited to, organic salts derived from amino acids, salts of primary, secondary, and tertiary amines, and salts of cyclic amines such as piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

[0095] Solvates refer to the combination or complex of one or more solvent molecules with the compounds of the present invention. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and ethanolamine. The compounds of the present invention may exist in unsolvated form or in solvated form with pharmaceutically acceptable solvents such as water, ethanol, etc., and the present invention encompasses both solvated and unsolvated forms.

[0096] The compounds of the present invention may contain asymmetric centers or chiral centers, and therefore different stereoisomeric forms exist. All stereoisomeric forms of the compounds of this invention, including but not limited to, diastereomers, enantiomers and hindered isomers, and mixtures thereof such as racemic mixtures, will form a part of the present invention. In this article, when the stereochemistry of any particular chiral atom is not determined, all stereoisomers are considered. In addition, the present invention relates to all geometric and positional isomers. The compounds of this invention may exist in different tautomeric forms, and all of these forms are included within the scope of the present invention. All stereoisomers of the compounds of this invention are expected to include mixture forms or pure or substantially pure forms. Can be separated by physical methods such as fractional crystallization, separation or crystallization of diastereomeric derivatives or by chiral column chromatography to split.

[0097] The compounds of the present invention may be used alone or in combination with other therapeutic agents. Combination therapy may provide a synergistic effect, that is, an effect achieved when the active ingredients are used together that is greater than the sum of the effects produced by the compounds when used separately.

[0098] The combination therapy may be administered in a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more regimens. The compounds may be administered together in a single pharmaceutical combination or separately, and when administered separately, they may be administered simultaneously or sequentially in any order.

[0099] The compounds of the present invention can be administered by any route suitable for the condition being treated. Suitable routes include, but are not limited to, oral, parenteral (including subcutaneous, intramuscular, intravenous, intraarterial, intradermal), vaginal, intraperitoneal, intrapulmonary, and intranasal. It should be understood that the preferred route may vary, for example, depending on the patient's condition. When the compound is administered orally, it can be formulated with a pharmaceutically acceptable carrier or excipient into a pill, capsule, tablet, or the like. When the compound is formulated into a parenteral, it can be formulated with a pharmaceutically acceptable parenteral carrier.

[0100] The present invention can administer the compound in any convenient formulation. The term "preparation" as used herein refers to a dosage form that is convenient for drug delivery and contains the compound of formula I of the present invention, such as, but not limited to, aqueous solution injections, powder injections, pills, powders, tablets, patches, suppositories, emulsions, creams, gels, granules, capsules, aerosols, sprays, powder aerosols, sustained-release agents, and controlled-release agents. These pharmaceutical excipients can be those conventionally used in various formulations, such as, but not limited to, isotonic agents, buffers, flavoring agents, excipients, fillers, binders, disintegrants, and lubricants; or they can be selected for compatibility with the substance, such as emulsifiers, solubilizers, antibacterial agents, analgesics, and antioxidants. Such excipients can effectively improve the stability and solubility of the compound contained in the composition or change the release rate and absorption rate of the compound, thereby improving the metabolism of the compound of the present invention in the body and enhancing the administration effect. In addition, excipients such as, but not limited to, gelatin, albumin, chitosan, polyether and polyester polymers, such as, but not limited to, polyethylene glycol, polyurethane, polycarbonate, and their copolymers, may be used to achieve specific drug delivery purposes or methods, such as sustained-release, controlled-release, and pulse delivery. The so-called "facilitating drug delivery" primarily includes, but is not limited to, enhancing therapeutic efficacy, increasing bioavailability, reducing toxic side effects, and improving patient compliance.

[0101] In the following examples, only some examples of the present invention are given in a manner to illustrate the inventive method. However, these examples do not limit the scope of the present invention in any way, and simple improvements to the preparation method of the present invention under the concept of the present invention all fall within the scope of protection claimed in the present invention. That is, when describing the present invention in conjunction with the enumerated embodiments, it should be understood that it is not intended to limit the present invention to those embodiments. On the contrary, the present invention is intended to include all variations, improvements and equivalent forms. Those skilled in the art will recognize many methods and materials similar or equivalent to those described in the application, and they can be used to realize the present invention.

[0102] In the examples described below, all temperatures are given in degrees Celsius unless otherwise stated. Unless otherwise stated, reagents were purchased from commercial suppliers such as Sinopharm, Shaoyuan, Anaiji, TCI, Sigma, etc. or custom-made.

[0103] Example 1 Synthesis of Compound 1

[0104] In a 50 mL round-bottom flask, the substrate (0.5 mmol) was weighed and dissolved in 27 mL of acetonitrile. An organic amine (5.0 mmol) and KCO (1.0 mmol) were added, and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous NaSO. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 38% yield.

[0105] Example 2 Synthesis of Compound 2

[0106] In a 50 mL round-bottom flask, the substrate (0.5 mmol) was weighed and dissolved in 27 mL of acetonitrile. An organic amine (5.0 mmol) and KCO (1.0 mmol) were added, and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous NaSO. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 44% yield.

[0107] 1 H NMR (500MHz, CDCl3) δ8.23(d,J=8.9Hz,1H),7.97(s,1H),7.58(dt,J=3.1,1.8Hz,2H),7.53–7.34(m,3H),6.98(dt,J=28.2,14.1Hz,1H),6. 90(d,J=2.3Hz,1H),4.47–4.06(m,2H),4.03–3.59(m,2H),2.86–2.72(m,1H),2.66–2.47(m,2H),1.18(t,J=7.4Hz,3H),1.04–0.74(m,4H).

[0108] 13 C NMR (126MHz, DMSO) δ174.65,163.09,159.02,157.43,153.50,130.10,126.95,124.09,123.36,117.55,11 5.10,113.63,101.04,68.31,55.17,47.62,40.02,39.85,39.69,39.52,39.35,39.19,39.02,30.04,6.20.

[0109] Example 3 Synthesis of Compound 3

[0110] In a 50 mL round-bottom flask, the substrate (0.5 mmol) was weighed and dissolved in 27 mL of acetonitrile. An organic amine (5.0 mmol) and KCO (1.0 mmol) were added, and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous NaSO. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 42% yield.

[0111] Example 4 Synthesis of Compound 4

[0112] Step 1: To a 1-L round-bottom flask, add 7-hydroxyisoflavone (0.040 mol), 400 mL of anhydrous acetone, 1,2-dibromoethane (0.403 mol), and potassium carbonate (0.080 mol). Heat under reflux overnight. Follow the reaction by TLC. After the solvent is evaporated, add 10 mL of water and 300 mL of ethyl acetate. Separate the organic layer, dry it over anhydrous NaSO, and concentrate to dryness. Purify the organic layer by silica gel column chromatography to obtain 12.98 g of 7-(2-bromoethoxy)isoflavone as a white solid (94% yield).

[0113] Step 2: To a 50 mL round-bottom flask, 7-(2-bromoethoxy)isoflavone (0.5 mmol), 27 mL of CH3CN, and cyclopropylamine (1.0 mmol) were added, followed by K2CO3 (1.0 mmol). The mixture was heated under reflux overnight, and the reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous Na2SO4. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 53% yield.

[0114] 1 HNMR (400MHz, DMSO) δ8.46 (s, 1H), 8.04 (d, J = 8.8Hz, 1H), 7.64–7.35 (m, 5H), 7.16 (s, 1H), 7.09 (d, J=8.8Hz,1H),4.17(t,J=5.4Hz,2H),2.99(t,J=5.3Hz,2H),2.23–2.09(m,1H),0.46–0.18(m,4H).

[0115] 13 CNMR(101MHz,DMSO)δ174.4,163.1,157.4,154.1,132.0,128.9,128.1,127.8,127.0,123.8,117.6,115.1,101.1,68.3,47.6,30.0,6.2.

[0116] HRMS(ESI):m / z,calcd for[M+H] + :322.1438; found:322.1439.

[0117] Example 5 Synthesis of Compound 5

[0118] To a 50 mL round-bottom flask were added 7-(2-bromoethoxy)isoflavone (0.5 mmol), 27 mL of CH₃CN, and 1-methylcyclopropylamine (1.0 mmol). K₂CO₃ (1.0 mmol) was then added and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was dried, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous Na₂SO₄. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 37% yield.

[0119] 1 H NMR(500MHz, CDCl3)δ8.20(d,J=8.9Hz,1H),7.93(s,1H),7.63–7.49(m,2H),7.47–7.40(m,2H),7.40–7.33(m,1H),6.99(dd,J=8.9, 2.4Hz,1H),6.85(d,J=2.3Hz,1H),4.14(t,J=5.3Hz,2H),3.13(t,J=5.3Hz,2H),1.32(s,3H),0.71–0.57(m,2H),0.48–0.36(m,2H).

[0120] 13 C NMR (126MHz, CDCl3) δ175.73,163.36,157.97,152.80,132.06,129.09,128.58,128 .22,127.91,125.38,118.61,115.00,100.81,68.75,44.82),34.98,22.10,14.60.

[0121] HRMS(ESI):m / z[M+H] + calcd for C 21 H 22 NO3 + :326.1600;found:336.1529.

[0122] Example 6 Synthesis of Compound 6

[0123] In a 50 mL round-bottom flask, the substrate (0.5 mmol) was weighed and dissolved in 27 mL of acetonitrile. An organic amine (5.0 mmol) and KCO (1.0 mmol) were added, and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous NaSO. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 32% yield.

[0124] Example 7 Synthesis of Compound 7

[0125] To a 50 mL round-bottom flask, 7-(2-bromoethoxy)isoflavone (0.5 mmol), 27 mL of CH₃CN, and cyclohexylamine (1.0 mmol) were added sequentially. K₂CO₃ (1.0 mmol) was added and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous Na₂SO₄. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 45% yield.

[0126] 1 H NMR (400MHz, DMSO) δ8.46(s,1H),8.03(d,J=8.9Hz,1H),7.72–7.30(m,5H),7.17(s,1H),7.09(d,J=8.9Hz,1H),4.16(t,J =5.4Hz,2H),2.95(t,J=5.4Hz,2H),2.43(t,J=10.0Hz,1H),2.33(d,J=65.9Hz,1H),1.88–1.49(m,5H),1.26–0.98(m,5H).

[0127] 13 C NMR (101MHz, DMSO) δ174.4,163.1,157.4,154.2,132.0,128.9,128.1,127 .8,127.0,123.8,117.6,115.2,101.1,68.6,56.0,44.7,32.6,25.8,24.4.

[0128] HRMS(ESI):m / z[M+H] + calcd for C 23 H 26 NO3 + :364.1907; found:364.1909.

[0129] Example 8 Synthesis of Compound 8

[0130] In a 50 mL round-bottom flask, the substrate (0.5 mmol) was weighed and dissolved in 27 mL of acetonitrile. An organic amine (5.0 mmol) and KCO (1.0 mmol) were added, and the mixture was heated under reflux overnight. The reaction was monitored by TLC. The solvent was evaporated, and 50 mL of water and 100 mL of ethyl acetate were added. The organic layer was separated and dried over anhydrous NaSO. The organic layer was concentrated to dryness and purified by silica gel column chromatography to obtain the title compound in a 32% yield.

[0131] Example 9 Synthesis of Compound 9

[0132] Compound 4 (2 mmol) was added to a 50 mL round-bottom flask and dissolved in 20 mL of methanol. Paraformaldehyde (20 mmol), sodium cyanoborohydride (10 mmol), and acetic acid (4 mmol) were then added. The mixture was stirred at room temperature overnight, and the reaction was monitored by TLC. The solvent was dried, and 100 mL of saturated sodium carbonate solution and 200 mL of ethyl acetate were added. The organic layer was separated, washed with saturated sodium chloride, dried over anhydrous Na2SO4, and concentrated to dryness. The title compound was obtained by silica gel column chromatography in a 72% yield.

[0133] 1 H NMR (500MHz, CDCl3) δ8.22(d,J=5.7Hz,1H),7.86(d,J=91.6Hz,1H),7.43(dd,J=82.0,59.1Hz,5H),7 .03(s,1H),6.88(s,1H),4.22(s,2H),3.04(s,2H),2.50(s,3H),1.78(s,1H),0.51(d,J=16.3Hz,4H).

[0134] 13 C NMR (126MHz, CDCl3) δ175.63,163.31,157.91,152.67,132.02,129.01,128.49,12 8.13,127.77,125.26,118.46,115.03,100.76,66.55,56.67,43.70,38.66,6.91..

[0135] HRMS(ESI):m / z[M+H] + calcd for C 21 H 22 NO3 + :336.16; found:336.1672.

[0136] Example 10 Synthesis of Compound 10

[0137] Compound 4 (2 mmol) was added to a 50 mL round-bottom flask and dissolved in 20 mL of pyridine. Acetic anhydride (20 mmol) was then added and stirred at room temperature overnight. The reaction was monitored by TLC. The solvent was dried, and 100 mL of 1 M hydrochloric acid and 200 mL of ethyl acetate were added. The organic layer was separated and washed with 1 M hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride. The organic layer was dried over anhydrous Na2SO4, concentrated to dryness, and purified by silica gel column chromatography to obtain the title compound in an 81% yield.

[0138] 1 H NMR (500MHz, CDCl3) δ8.25(t,J=29.2Hz,1H),7.96(s,1H),7.55(t,J=18.2Hz,2H),7.45(t,J=7.4Hz,2H),7.39(t,J=7.3Hz,1H),6.98(dt,J=21. 9,10.9Hz,1H),6.90(d,J=1.9Hz,1H),4.47–4.11(m,2H),3.78(dt,J=30 .5,5.4Hz,2H),2.99–2.63(m,1H),2.35–1.98(m,3H),1.09–0.68(m,4H).

[0139] 13 C NMR (126MHz, CDCl3) δ175.63,174.16,163.08,157.95,152.76,131.98,129.02,128.5 1,128.16,127.87,125.29,118.59,114.91,100.72,66.40,46.77,32.17,22.82,9.79.

[0140] Example 11 Synthesis of Compound 11

[0141] Compound 4 (2 mmol) was added to a 50 mL round-bottom flask and dissolved in 20 mL of pyridine. Propionic anhydride (20 mmol) was then added and stirred at room temperature overnight. The reaction was monitored by TLC. The solvent was dried, and 100 mL of 1 M hydrochloric acid and 200 mL of ethyl acetate were added. The organic layer was separated and washed with 1 M hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride. The organic layer was dried over anhydrous Na2SO4, concentrated to dryness, and purified by silica gel column chromatography to obtain the title compound in an 83% yield.

[0142] 1H NMR (500MHz, CDCl3) δ8.23(d,J=8.9Hz,1H),7.97(s,1H),7.58(dt,J=3.1,1.8Hz,2H),7.53–7.34(m,3H),6.98(dt,J=28.2,14.1Hz,1H),6. 90(d,J=2.3Hz,1H),4.47–4.06(m,2H),4.03–3.59(m,2H),2.86–2.72(m,1H),2.66–2.47(m,2H),1.18(t,J=7.4Hz,3H),1.04–0.74(m,4H).

[0143] 13 C NMR (126MHz, CDCl3) δ177.35,175.70,163.17,158.02,152.79,132.03,129.07,128.56,1 28.21,127.93,125.36,118.62,114.97,100.75,66.53,47.02,31.41,27.56,9.73,9.23.

[0144] Example 12 Synthesis of Compound 12

[0145] Compound 4 (2 mmol) was added to a 50 mL round-bottom flask and dissolved in 20 mL of methanol. Acetone (20 mmol), sodium cyanoborohydride (10 mmol), and acetic acid (4 mmol) were then added. The mixture was stirred at room temperature overnight, and the reaction was monitored by TLC. The solvent was dried, and 100 mL of saturated sodium carbonate solution and 200 mL of ethyl acetate were added. The organic layer was separated, washed with saturated sodium chloride, dried over anhydrous Na2SO4, and concentrated to dryness. The title compound was obtained by silica gel column chromatography in a 75% yield.

[0146] 1H NMR(500MHz, CDCl3)δ8.21(d,J=8.9Hz,1H),7.95(s,1H),7.60–7.52(m,2H), 7.44(dd,J=10.2,4.7Hz,2H),7.41–7.35(m,1H),6.99(dd,J=8.9,2.3Hz,1H), 6.86(d,J=1.6Hz,1H),4.15(s,2H),3.14(s,1H),3.03(s,2H),1.98(s,1H),1.10(s,6H),0.49(d,J=37.0Hz,4H).

[0147] 1H NMR(500MHz,MeOD)δ8.25(s,1H),8.13(d,J=9.3Hz,1H),7.58–7.52(m,2H),7.44(t,J=7.4Hz,2H),7.41–7.36(m,1H),7.11–7.06(m,2H),4.2 5(t,J=6.1Hz,2H),3.22–3.13(m,1H),3.07(t,J=6.1Hz,2H),2.11–1.92(m,1H),1.14(d,J=6.7Hz,6H),0.59–0.52(m,2H),0.49–0.43(m,2H).

[0148] 13 C NMR (126MHz, CDCl3) δ175.71,163.51,158.03,152.69,132.10,129.08,128.55,128.1 7,127.84,125.33,118.44,115.09,100.76,68.10,53.25,49.13,34.54,18.97,7.23.

[0149] HRMS(ESI):m / z[M+H] + calcd for C 23 H 26 NO3 + :364.1913; found:364.1906.

[0150] The chemical structures that appear in the tables or figures below are as follows:

[0151] Example 13: Therapeutic effect of the compounds of the present invention on a pneumonia model in mice infected with influenza A (H1N1) virus FM1 strain

[0152] 1. Test materials

[0153] 1.1 Test drugs: Compound 4, Compound F1, Compound F2, Compound F3

[0154] 1.2 Positive control drug

[0155] Ribavirin Granules: Manufacturer: Sichuan Baili Pharmaceutical Co., Ltd. Indications: This product is indicated for viral pneumonia and bronchitis caused by respiratory syncytial virus, and herpes simplex virus infections of the skin. Main ingredient: Ribavirin. Appearance: White or off-white soluble granules. Specifications: 50 mg / bag, 18 bags / box. Dosage: Oral, 150 mg three times daily. Storage: Store tightly closed in a dry place.

[0156] 1.3 Experimental animals

[0157] 1.4 Virus strains

[0158] 1.5 Test equipment

[0159] 2 Test methods

[0160] 2.1 Dosage design and preparation

[0161] Test drug

[0162] Ribavirin granules

[0163] 2.2 Modeling and drug administration

[0164] ICR mice were randomly divided into the following groups according to their weight: normal control group, model control group, ribavirin control group, compound 4, compound F1, compound F2, and compound F3. Each drug had two dose groups, with 10 mice in each group. Except for the normal control group, the mice were lightly anesthetized with ether and 15 LD 50 Each mouse was inoculated with 30 μl of H1N1 influenza virus strain FM1 via intranasal drip. Drug administration began on the day of infection, with 0.2 ml / 10 g administered orally once daily for four consecutive days. A normal control group and a model control group were administered distilled water via intragastric gavage under the same conditions. On the fifth day, the mice were weighed and dissected, and lung weights were measured. Lung index and lung index inhibition rate were calculated. Results were statistically analyzed using the t-test for intergroup comparisons.

[0165] Lung index (%) = lung wet weight (g) × 100 / body weight (g)

[0166] 3 Test results

[0167] Table 1 The therapeutic effects of the compounds of the present invention on the pneumonia model of mice infected with influenza virus H1N1 / FM1 strain

[0168] Note: Compared with the normal group ## P<0.01; compared with the model control group, * P<0.05

[0169] The results in Table 1 show that after infection of mice with influenza A (H1N1) virus strain FM1, the lung index of mice increased significantly, with a significant difference compared to the normal control group (P<0.01). After treatment with Compound 4, Compound F1, Compound F2, and Compound F3 for 4 days starting on the day of infection, the 50 mg / kg / d dose of Compound 4 significantly reduced the lung index of mice after infection, with a significant difference compared to the model control group (P<0.05). Compound F1 at 50 mg / kg showed a trend toward lowering the lung index, while Compounds F2 and F3 had no significant effect on the lung index of mice. Compound 4 was more potent than Compound F1, indicating that the 7-position substituent has a significant influence on the anti-influenza efficacy of this type of isoflavone derivative. Compound 4 was also more potent than Compounds F2 and F3, indicating that the position and structure of the substituent have a significant influence on the anti-influenza efficacy of this type of isoflavone derivative.

[0170] Example 14: Therapeutic effects of the compounds of the present invention on pneumonia models in mice infected with influenza A (H1N1) virus strains FM1 and PR8

[0171] 1. Test materials

[0172] 1.1 Test drugs: Compound 4, Compound F4, Compound F5, Compound 5, Compound 7

[0173] 1.2 Positive control drug

[0174] Oseltamivir phosphate capsules (Tamiflu) Manufacturer: Hoffmann-La Roche GmbH, Basel, Switzerland. Indications: For the treatment of influenza A and B in adults and children aged 1 year and above; for the prevention of influenza A and B in adults and adolescents aged 13 years and above. Main ingredient: Oseltamivir phosphate. Properties: This product is a gray and light yellow capsule containing a white to yellowish-white powder that may contain lumps. Specifications: 75 mg / capsule, 10 capsules / box, based on oseltamivir. Dosage and Administration: Oral, for adults and adolescents aged 13 years and above, 75 mg each time, twice a day for 5 days. Storage conditions: Store in a sealed container.

[0175] 1.3 Experimental animals

[0176] 1.4 Virus strains

[0177] 1.5 Test equipment

[0178] 2 Test methods

[0179] 2.1 Dosage design and preparation

[0180] Test drug

[0181] Oseltamivir phosphate capsules

[0182] 2.2 Test steps

[0183] ICR mice were randomly divided into the following groups according to weight: normal control group, model control group, oseltamivir control group, compound 4, compound F4, compound F5, compound 5, and compound 7. Each drug had two dose groups, with 10 mice in each group. Except for the normal control group, the mice were lightly anesthetized with ether and 15 LD 50 Each mouse was inoculated with H1N1 influenza virus (FM1 / PR8 strain) by intranasal drip (30 μl). Administration began on the day of infection, with 0.2 ml / 10 g administered orally once daily for four consecutive days. A normal control group and a model control group were administered distilled water by intragastric gavage under the same conditions. On the fifth day, the mice were weighed and dissected, and lung weights were measured. Lung index and lung index inhibition rate were calculated. Results were statistically analyzed using the t-test for intergroup comparisons.

[0184] Lung index (%) = lung wet weight (g) × 100 / body weight (g)

[0185] 3 Test results

[0186] Table 2 The therapeutic effects of the compounds of the present invention on the pneumonia model of mice infected with influenza virus H1N1 / FM1 strain

[0187] Note: Compared with the normal group ## P<0.01; compared with the model control group, ** P<0.01, * P<0.05

[0188] The results in Table 2 show that after infection with influenza A (H1N1) virus strain FM1, mice experienced a significant increase in lung index (LI) compared to the normal control group (P < 0.01). After treatment with the compounds of the present invention for four days, starting on the day of infection, compound 4 at a dose of 40 mg / kg / day significantly reduced the LI after infection, showing a significant difference compared to the model control group (P < 0.01), with a LI inhibition rate of 54.04%. Compound 7 at a dose of 40 mg / kg / day showed a trend toward reducing LI. However, compounds F4, F5, and 5 had no effect on reducing LI after infection. The pharmacological effects of compound F4, compound F5, compound 5, and compound 7 were all reduced relative to compound 4. Among them, compound F4 and compound F5 were metabolites of compound 4 in the body, compound 5 was a derivative with 2-(1-methylcyclopropylamino)ethoxy substituent at position 7, and compound 7 was a derivative with 2-(cyclohexylamino)ethoxy substituent at position 7, which proved that the 2-(cyclopropylamino)ethoxy substituent at position 7 had a very important effect on the pharmacological effects of this type of isoflavone derivatives.

[0189] Table 3 The therapeutic effect of compound 4 of the present invention on the pneumonia model of mice infected with influenza virus H1N1 / PR8 strain

[0190] Note: Compared with the normal group ## P<0.01; compared with the model control group, * P<0.05, ** P<0.01

[0191] The results in Table 3 show that after mice were infected with influenza A (H1N1) virus PR8 strain, the lung index of mice increased significantly, which was significantly different from that of the normal control group (P<0.01). After 4 days of treatment with compound 4 starting on the day of infection, compound 4 at a dose of 15 mg / kg / d significantly reduced the lung index of mice after infection, which was significantly different from that of the model control group (P<0.01). The lung index inhibition rate was 60.27%. The inhibition rate of oseltamivir at a dose of 27.5 mg / kg / d was 58.89%.

[0192] Example 15: Therapeutic effect of the compounds of the present invention on a mouse pneumonia model infected with human coronavirus 229E

[0193] 1. Test materials

[0194] 1.1 Test drugs: Compound 4, Compound F1, Compound F2, Compound F3.

[0195] 1.2 Positive drug: Chloroquine phosphate tablets, Sichuan Shenghe Pharmaceutical Co., Ltd. Specification: 0.25g / tablet, Usage and Dosage: 0.5g / 60kg / d, oral.

[0196] 1.3 Experimental animals

[0197] 1.4 Strains and Cells: Human coronavirus 229E (HCoV-229E) was provided by the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, passaged in our laboratory, and stored at −80°C until use. Human embryonic lung fibroblast MRC5 cells were purchased from the Beijing Beina Chuanglian Biotechnology Research Institute, passaged in our laboratory, and stored in liquid nitrogen until use.

[0198] 1.5 Test equipment

[0199] 2 Test methods

[0200] 2.1 Drug dosage design and preparation

[0201] Test drug

[0202] Chloroquine phosphate tablets

[0203] 2.2 Virus passage

[0204] Take a 25cm2 monolayer of MRC-5 cells 2 The culture flask was cultured, the culture medium was discarded, the cell surface was rinsed three times with cell maintenance medium, 5 ml of cell maintenance medium was added, and then 200 μl of HCoV-229E virus solution was added. The cells were cultured in a 37°C 5% CO2 incubator for 72 to 96 hours. The cell pathological changes were observed under an inverted microscope every day until 80% of the cells showed obvious pathological changes (CPE). The cell culture flask was placed in a -80°C low-temperature refrigerator for freezing. The virus solution was repeatedly frozen and thawed three times and then used for virus titer determination.

[0205] 2.3 Virus titer determination

[0206] Take a 96-well plate containing MRC5 cells grown as a monolayer, discard the culture medium, rinse the cells three times with cell maintenance medium, and then inoculate the HCoV-229E virus at different titers, diluted 10-fold (10-1 to 10-8), for a total of eight dilutions, 100 μl per well. Four replicates of each dilution should be prepared. A normal cell control should also be included. The 96-well plate should be incubated in a 37°C, 5% CO2 incubator for 72-96 hours. Cytopathic effects should be observed daily under an inverted microscope, and the cytopathic effect of each well should be recorded. The 50% cytopathic concentration (TCID50) should be calculated using the Reed-Muench method.

[0207] 2.4 Construction and drug administration of a mouse model of human coronavirus pneumonia

[0208] BALB / c mice were randomly divided into normal control group, model control group, chloroquine phosphate control group, compound 4, compound F1, compound F2, and compound F3 according to body weight, with 10 mice in each group, half male and half female. Except for the normal control group, mice in other groups were lightly anesthetized with ether and then treated with 100TCID 50 HCoV-229E was inoculated intranasally with 50 μl per mouse every other day for a total of two infections. On the day of the initial infection, each group was administered once daily for four consecutive days. One day after the final dose, mice were weighed, and lungs were dissected and weighed. Lung index and inhibition rate were calculated.

[0209] 3 Test results

[0210] Table 4 Effects of the compounds of the present invention on the pneumonia model of mice infected with human coronavirus 229E

[0211] Note: Compared with the normal control group ## P<0.01; compared with the model control group ** P<0.01.

[0212] The results in Table 4 show that after mice were infected with human coronavirus 229E, the lung index of mice in the model control group increased significantly, with a significant difference compared with the normal control group (P<0.01); the lung index of mice in the 50 mg / kg and 40 mg / kg dose groups of compound 4 was significantly reduced, with a significant difference compared with the model control group (P<0.05), with inhibition rates of 41.00% and 41.85%, respectively. Compound F1, compound F2, and compound F3 had no significant effect on the lung index of mice. The efficacy of compound 4 is stronger than that of compound F1, indicating that the 7-position substituent has a very important effect on the anti-coronavirus efficacy of this type of isoflavone derivative; and compound 4 is more potent than compounds F2 and F3, indicating that the position and structure of the substituent have a very important effect on the anti-coronavirus efficacy of this type of isoflavone derivative.

[0213] Example 16: Effects of the compounds of the present invention on the pneumonia model of mice infected with coronavirus 229E

[0214] The test reagents, test instruments and test methods are the same as above.

[0215] Test samples: Compound 4, Compound F4, Compound F5, Compound 5, Compound 7

[0216] Animal Certificate: BALB / c mice 1100112011066562881 / 718

[0217] Table 5 Effects of the compounds of the present invention on the coronavirus 229E-infected pneumonia mouse model

[0218] Note: Compared with the normal control group ## P<0.01; compared with the model control group ** P<0.01, * P<0.05

[0219] The results in Table 5 show that after mice were infected with human coronavirus 229E, the lung index of mice increased significantly, which was significantly different from that of the normal control group (P<0.01). After 4 days of treatment with the compounds of the present invention starting on the day of infection, compound 4 at doses of 30 mg / kg / d, 15 mg / kg / d, and 7.5 mg / kg / d significantly reduced the lung index of mice after infection, which was significantly different from that of the model control group (P<0.01, P<0.05). The lung index inhibition rates were 86.46%, 76.52%, and 44.34%, respectively. The 15 mg / kg / d dose of compound 7 reduced the lung index, which was significantly different from that of the model control group (P<0.05), with an inhibition rate of 41.56%. Compound F4, compound F5, and compound 5 had no effect on reducing the lung index of mice after infection. The efficacy of compound F4, compound F5, compound 5, and compound 7 relative to compound 4 is all reduced, proving that the 2-(cyclopropylamino)ethoxy substituent at position 7 has a very important effect on the anti-coronavirus efficacy of this type of isoflavone derivatives.

[0220] Example 17: Therapeutic effect of compound 4 on the pneumonia model of mice infected with human coronavirus OC43

[0221] The test reagents, test instruments and test methods are the same as above.

[0222] Test sample: Compound 4

[0223] Animal Certificate: BALB / c mouse 110011211110038632

[0224] Table 6 Effects of compound 4 of the present invention on the pneumonia model of mice infected with human coronavirus OC43

[0225] Note: Compared with the normal control group ## P<0.01; compared with the model control group ** P<0.01.

[0226] The results in Table 6 show that after mice were infected with human coronavirus OC43 virus, the lung index of mice increased significantly, which was significantly different from that of the normal control group (P<0.01). After 4 days of treatment with compound 4 starting on the day of infection, compound 4 at a dose of 15 mg / kg / d significantly reduced the lung index of mice after infection, which was significantly different from that of the model control group (P<0.05). The lung index inhibition rate was 47.43%. The inhibition rate of chloroquine phosphate at a dose of 90 mg / kg / d was 42.72%.

[0227] Example 18: Effect of Compound 4 of the Present Invention on Pneumonia Model in Mice Infected with Parainfluenza Virus

[0228] 1. Test materials

[0229] 1.1 Test drug: Compound 4

[0230] 1.2 Ribavirin Granules. Manufacturer: Sichuan Baili Pharmaceutical Co., Ltd. Indications: This product is indicated for viral pneumonia and bronchitis caused by respiratory syncytial virus, and herpes simplex virus infections of the skin. Main ingredient: Ribavirin. Appearance: White or off-white soluble granules. Specifications: 50 mg / bag, 18 bags / box. Dosage and Administration: Oral, 150 mg three times daily. Storage: Store tightly closed in a dry place.

[0231] 1.3 Experimental animals

[0232] 1.4 Virus strain: Parainfluenza virus, purchased from ATCC, USA, and stored at -80°C in our laboratory.

[0233] 1.5 Test equipment

[0234] 2 Test methods

[0235] 2.1 Dosage design and preparation

[0236] Test drug

[0237] Ribavirin granules

[0238] 2.2 Modeling and drug administration

[0239] Sixty ICR mice, SPF grade, weighing 13-15 g, were randomly divided into 6 groups according to body weight: normal control group, model control group, ribavirin group, and compound 4 three dose groups, with 10 mice in each group, half male and half female. Except for the normal control group, the mice in other groups were lightly anesthetized with ether and infected with 100 TCID 50Parainfluenza virus Sendai strain, 45 μl per mouse. Each group of mice was administered the corresponding drug after infection. The normal control group and the model control group were given distilled water under the same conditions for four consecutive days. On the fifth day, the mice were weighed, and lung tissue was isolated and measured.

[0240] Lung index = lung weight × 100 / body weight,

[0241] Table 7 Effects of compound 4 on the pneumonia model of mice infected with parainfluenza virus

[0242] Note: Compared with the normal control group ## P<0.01; compared with the model control group * P<0.05

[0243] The results in Table 7 show that after mice were infected with parainfluenza virus, the lung index of mice in the model control group increased significantly, with a significant difference compared with the normal control group (P<0.01); the lung index of mice in the 15 mg / kg dose group of compound 4 decreased significantly, with a significant difference compared with the model control group (P<0.05). The three dose groups had a good dose-effect correlation, and the inhibition rate of the high-dose group of compound 4 was 46.39%.

[0244] Example 19: In vitro anti-novel coronavirus (SARS-CoV-2) effect of compound 4 of the present invention

[0245] 1. Test materials

[0246] 1.1 Test drug: Compound 4

[0247] 1.2 Cell line: VeroE6 cells were maintained by the Virology Laboratory of the State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health.

[0248] 1.3 Virus strain: SARS-CoV-2, titer is TCID 50 =10 -6 / 100μL, stored at -80℃ in the National Key Laboratory of Biosafety Testing (P3 Laboratory) of the Health and Quarantine Institute of Guangzhou Customs Technology Center; the virus titer used was 100TCID 50 .

[0249] 2 Test methods

[0250] 2.1 Sample preparation

[0251] Drug name, experimental concentration and group

[0252] 2.2 Antiviral experiments of test drugs

[0253] ① Sterile 96-well culture plate, add 100 μL of 2×10 5 cells / mL VeroE6 cells, cultured at 37°C 5% CO2 for 24 h;

[0254] ② Add 100 TCID 50 Virus solution 100 μL / well, adsorb for 2 h in a 37°C, 5% CO2 incubator;

[0255] ③ After 2 hours, discard the cell culture medium in the 96-well culture plate; dilute the test drug to the concentrations listed in Table 1, replicate three wells for each concentration, and add 100 μl of the above solution to each well;

[0256] ④ Set up cell control, blank control (solvent control) and virus control (negative control) at the same time;

[0257] ⑤ Incubate the cells in a 37°C, 5% CO2 incubator for 3-4 days;

[0258] ⑥ Observe the cytopathic effect (CPE) under an optical microscope. The degree of cytopathic effect was recorded according to the following 6-level scale: "-" no cytopathic effect; "±" less than 10% cytopathic effect; "+" about 25% cytopathic effect; "++" about 50% cytopathic effect; "+++" about 75% cytopathic effect; "++++" more than 75% cytopathic effect. The median effective concentration (IC50) was calculated using the Reed-Muench method or GraphPad Prism 5.0. 50 ) Efficacy criteria: The concentration that inhibits viral CPE by 50% is considered to be effective.

[0259] 3 Test results

[0260] The cytopathic effect (CPE) was observed and the experimental results were recorded. The half effective concentration (IC50) was calculated using the Reed-Muench method or GraphPad Prism5.0. 50 ), the experimental results are as follows

[0261] Table 8 Anti-novel coronavirus efficacy results of compound 4

[0262] The results of the efficacy test of compound 4 against the new coronavirus are shown in Figure 1.

[0263] The results in Table 8 show that drug compound 4 has an inhibitory effect on the cytopathic effect of Vero E6 cells infected with the new coronavirus (SARS-CoV-2) in vitro.

[0264] Example 20: Study on the mechanism of action of compound 4 of the present invention against SARS-Cov-2 in vitro

[0265] 1. Binding to ACE2 receptor of 293T cells

[0266] Purpose of the experiment: To observe the binding effect of the test sample with ACE-2 receptor and to find the possible mechanism of action.

[0267] Instruments and materials

[0268] Test drugs: Compound 4, Compound F1, Compound F2, Compound F3

[0269] SHIMADZU LC-2040C 3D high-performance liquid chromatograph (Japan); Sartorius 1712 electronic analytical balance; Fulham FCR1002-UF ultrapure water preparation machine (Qingdao Fulham Technology Co., Ltd.); SHZ-D(III) circulating water vacuum pump (Gongyi Yingyu Yuhua Instrument Factory); SB-5200DTD ultrasonic cleaner (Ningbo Xinzhi Biotechnology Co., Ltd.); and pipette (Eppendorf, Germany).

[0270] The 293T cell line with high expression of ACE2 receptor was constructed in the laboratory.

[0271] Methanol was of chromatographic grade, water was ultrapure water, and other reagents were of analytical grade.

[0272] Test methods

[0273] Binding of samples to ACE2 receptors of 293T cells

[0274] Sample preparation

[0275] Accurately weigh 5 mg each of compound 4, compound F1, compound F2, and compound F3 of the present invention, fully dissolve them with chromatographic grade methanol, transfer them to a 10 mL volumetric flask, and adjust the volume to obtain a pharmaceutical stock solution of the compound series of the present invention with a concentration of 0.5 mg / mL. Protect from light and refrigerate until use; dilute to the required concentration when needed. The stock solution is freshly prepared every week.

[0276] CMC chromatographic conditions

[0277] An ACE2-293T / CMC cell membrane chromatography column (10 × 2.0 mm) was used with water as the mobile phase at a flow rate of 0.2 mL / min, a column temperature of 37°C, an injection volume of 10 μL, and DAD detection. Positive control: chloroquine phosphate.

[0278] Test results

[0279] The cell membrane chromatogram of the compound of the present invention is shown in FIG2 .

[0280] Table 9 KD values ​​of samples and chloroquine phosphate

[0281] 2. Evaluation of the functional effects of compound 4 on ACE2-293T cells

[0282] Experimental method: Detection of intracellular Ca2+ current changes: cells were inoculated into 96-well plates. After overnight, the culture medium was discarded, and the cells were washed with CIB. Fluo-3 and AM incubation solution were added and incubated in the incubator for 40 minutes. The incubation solution was discarded, and the cells were washed with CIB. Under a fluorescence microscope, after discarding CIB, drugs were added to each well in turn to observe the changes in cell fluorescence intensity before and after drug addition. The cells were observed under a fluorescence microscope for 2 minutes, and drug stimulation was added 10 seconds after the start of observation and photography.

[0283] Experimental results: Intracellular Ca 2+ Flow changes: Compound 4 at 10 μg / mL stimulated calcium mobilization in ACE2-293T cells. With increasing concentrations, the degree of calcium fluctuation in ACE2-293T cells increased in a dose-dependent manner. Calcium imaging results of compound 4 in ACE2-293T cells are shown in Figure 3.

[0284] Example 21: Effect of Compound 4 on the Levels of Inflammatory Factors in Lung Tissue of Mice Infected with Influenza Virus

[0285] Lung tissue samples: Therapeutic effect of compound 4 on the pneumonia model of mice infected with influenza virus H1N1 / FM1 strain

[0286] Test method: Detection of inflammatory factors in mouse lung tissue (ELISA method)

[0287] Tissue homogenate sample: After weighing and collecting lung tissue from mice, store at -4°C. Weigh 50 mg of lung tissue and add 500 μL of normal saline. Homogenize the tissue using an ultrasonic cell disruptor. Centrifuge at 1000 x g for 10 minutes at -4°C in a low-temperature high-speed centrifuge. Aspirate the supernatant, aliquot, and store at -80°C until needed. Avoid repeated freeze-thaw cycles.

[0288] Sample preparation: The sample was diluted 2-fold with diluent before testing, i.e. 50 μL serum + 50 μL diluent.

[0289] Remove the microplate from the sealed bag that has been equilibrated to room temperature, and add different concentrations of standards, experimental samples or quality control products to the corresponding wells, 100μL per well. Seal the reaction wells with sealing tape and incubate at room temperature for 2 hours. Wash the plate with washing solution and repeat the operation 4 times. After the last wash, turn the plate upside down and pat dry any residual liquid on absorbent paper; add 100μL of enzyme-labeled detection antibody to each microwell. Seal the reaction wells with sealing tape and incubate at room temperature for 2 hours. Repeat the washing operation in step 4, add 100μL of colorimetric substrate to each microwell, and incubate at room temperature for 30 minutes. Be careful to avoid light. Within 30 minutes after adding 100μL of stop solution to each microwell, measure the absorbance value at 450nm using a microplate reader. Calculate the results.

[0290] The results in Figures 4 and 5 show that after mice were infected with the influenza virus H1N1 / FM1 strain, the levels of IFN-β and TNF-a in the lung tissue of the mice increased, which was significantly different from the normal control group (p<0.01). After 4 days of administration, compound 4 significantly reduced the levels of IFN-β and TNF-a in the lung tissue of the infected mice, which was significantly different from the model control group (p<0.01).

[0291] Example 22: Effect of Compound 4 on the Levels of Inflammatory Factors in Lung Tissue of Mice Infected with Coronavirus 229E

[0292] Lung tissue samples: Therapeutic effect of compound 4 on the pneumonia model of mice infected with human coronavirus 229E

[0293] The results in Figures 6 and 7 show that after mice were infected with human coronavirus 229E, the levels of IL-1 and IL-10 in the lung tissue of mice increased, which was significantly different from the normal control group (p<0.01). After 4 days of administration, compound 4 significantly reduced the levels of IL-1 and IL-10 in the lung tissue of infected mice, which was significantly different from the model control group (p<0.01).

[0294] Example 23 Therapeutic Effects of the Compounds of the Present Invention on Pneumonia Model in Mice Infected with Human Coronavirus 229E

[0295] 1. Test materials

[0296] 1.1 Test drugs: Compound 4, Compound 9, Compound 10, Compound 11, Compound F1.

[0297] 1.2 Positive drug: Chloroquine phosphate tablets, Sichuan Shenghe Pharmaceutical Co., Ltd. Specification: 0.25g / tablet, Usage and Dosage: 0.5g / 60kg / d, oral.

[0298] 1.3 Experimental animals

[0299] 1.4 Strains and Cells: Human coronavirus 229E (HCoV-229E) was provided by the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, passaged in our laboratory, and stored at −80°C until use. Human embryonic lung fibroblast MRC5 cells were purchased from the Beijing Beina Chuanglian Biotechnology Research Institute, passaged in our laboratory, and stored in liquid nitrogen until use.

[0300] 1.5 Test equipment

[0301] 2 Test methods

[0302] 2.1 Drug dosage design and preparation

[0303] Test drug

[0304] Chloroquine phosphate tablets

[0305] 2.2 Virus passage

[0306] Take a 25cm2 monolayer of MRC-5 cells 2 The culture flask was cultured, the culture medium was discarded, the cell surface was rinsed three times with cell maintenance medium, 5 ml of cell maintenance medium was added, and then 200 μl of HCoV-229E virus solution was added. The cells were cultured in a 37°C 5% CO2 incubator for 72 to 96 hours. The cell pathological changes were observed under an inverted microscope every day until 80% of the cells showed obvious pathological changes (CPE). The cell culture flask was placed in a -80°C low-temperature refrigerator for freezing. The virus solution was repeatedly frozen and thawed three times and then used for virus titer determination.

[0307] 2.3 Virus titer determination

[0308] Take a 96-well plate with MRC5 cells grown into a monolayer, discard the culture medium, wash the cells three times with cell maintenance medium, and then add 10 times (10 -1 ~10 -8 ) HCoV-229E virus solution of different titers was diluted and inoculated, with a total of 8 dilutions, 100 μl / well, and 4 replicates were made for each dilution. A normal cell control was also set up. The 96-well plate was placed in a 37°C, 5% CO2 incubator for 72-96 hours. The cytopathic effect was observed under an inverted microscope every day, and the cytopathic effect of each well was recorded. The 50% cytopathic concentration (TCID) was calculated according to the Reed-Muench method. 50 ).

[0309] 2.4 Construction and drug administration of a mouse model of human coronavirus pneumonia

[0310] BALB / c mice were randomly divided into normal control group, model control group, chloroquine phosphate control group, and one dose group for each drug, compound 4, compound 9, compound 10, and compound 11. Each group had 10 mice, half male and half female. Except for the normal control group, the mice in other groups were lightly anesthetized with ether and then treated with 100TCID 50 HCoV-229E was inoculated intranasally with 50 μl per mouse every other day for a total of two infections. On the day of the initial infection, each group was administered once daily for four consecutive days. One day after the final dose, mice were weighed, and lungs were dissected and weighed. Lung index and inhibition rate were calculated.

[0311] Lung index = lung wet weight (g) × 100 / body weight (g)

[0312] 3 Test results

[0313] Table 10 Effects of the compounds of the present invention on the pneumonia model of mice infected with human coronavirus 229E

[0314] Note: Compared with the normal control group # P<0.05; compared with the model control group * P<0.05

[0315] The results in Table 10 show that after mice were infected with human coronavirus 229E, the lung index of mice in the model control group increased significantly, which was significantly different from that in the normal control group (P<0.05); the lung index of mice in the 7.5 mg / kg / d dose group of compound 4 and compound 9 decreased significantly, which was significantly different from that in the model control group (P<0.05).

[0316] Example 24 Effects of the compounds of the present invention on the pneumonia model of mice infected with parainfluenza virus

[0317] 1. Test materials

[0318] 1.1 Test drugs: Compound 4, Compound 9, Compound 10, Compound 11, Compound 12, Compound 2.

[0319] 1.2 Ribavirin Granules. Manufacturer: Sichuan Baili Pharmaceutical Co., Ltd. Indications: This product is indicated for viral pneumonia and bronchitis caused by respiratory syncytial virus, and herpes simplex virus infections of the skin. Main ingredient: Ribavirin. Appearance: White or off-white soluble granules. Specifications: 50 mg / bag, 18 bags / box. Dosage and Administration: Oral, 150 mg three times daily. Storage: Store tightly closed in a dry place.

[0320] 1.3 Experimental animals

[0321] 1.4 Virus strain: Parainfluenza virus, purchased from ATCC, USA, and stored at -80°C in our laboratory.

[0322] 1.5 Test equipment

[0323] 1.6 Test site: ABSL-2 laboratory of Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences

[0324] 2 Test methods

[0325] 2.1 Dosage design and preparation

[0326] Test drug

[0327] Ribavirin granules

[0328] 2.2 Modeling and drug administration

[0329] 150 SPF ICR mice weighing 13-15 g were randomly divided into 15 groups according to body weight: normal control group, model control group, ribavirin group, compound 4, compound 9, compound 10, compound 11, compound 12, and compound 2, each with two doses, 10 mice in each group, half male and half female. Except for the normal control group, mice in other groups were lightly anesthetized with ether and intranasally infected with 100 TCID 50 Parainfluenza virus Sendai strain, 45 μl per mouse. Each group of mice was administered the corresponding drug after infection. The normal control group and the model control group were given distilled water under the same conditions for four consecutive days. On the fifth day, the mice were weighed, and lung tissue was isolated and measured.

[0330] Lung index = lung weight (g) × 100 / body weight (g)

[0331] Table 11 Effects of the compounds of the present invention on the pneumonia model of mice infected with parainfluenza virus

[0332] Note: Compared with the normal control group # P<0.05; compared with the model control group * P<0.05

[0333] The results in Table 11 show that after mice were infected with parainfluenza virus, the lung index of mice in the model control group increased significantly, which was significantly different from that in the normal control group (P<0.01); the lung index of mice in the 15 mg / kg / d and 7.5 mg / kg / d dose groups of compound 4, compound 9, and compound 12 decreased significantly, which was significantly different from that in the model control group (P<0.05).

[0334] Example 25 Therapeutic effects of the compounds of the present invention on pneumonia models in mice infected with influenza A viruses H1N1 / PR8 and H1N1 / FM1

[0335] 1. Test materials

[0336] 1.1 Test drugs: Compound 9, Compound 12, Compound 2.

[0337] 1.2 Positive control drug

[0338] Oseltamivir phosphate capsules (Tamiflu) Manufacturer: Hoffmann-La Roche GmbH, Basel, Switzerland. Indications: For the treatment of influenza A and B in adults and children aged 1 year and above; for the prevention of influenza A and B in adults and adolescents aged 13 years and above. Main ingredient: Oseltamivir phosphate. Properties: This product is a gray and light yellow capsule containing a white to yellowish-white powder that may contain lumps. Specifications: 75 mg / capsule, 10 capsules / box, based on oseltamivir. Dosage and Administration: Oral, for adults and adolescents aged 13 years and above, 75 mg each time, twice a day for 5 days. Storage conditions: Store in a sealed container.

[0339] 1.3 Experimental animals

[0340] 1.4 Virus strains

[0341] 1.5 Test equipment

[0342] 1.6 Test site: ABSL-2 laboratory of Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences

[0343] 2 Test methods

[0344] 2.1 Dosage design and preparation

[0345] Test drug

[0346] Oseltamivir phosphate capsules

[0347] 2.2 Experimental steps

[0348] ICR mice were randomly divided into 9 groups according to weight: normal control group, model control group, oseltamivir phosphate control group, compound 9, compound 12, and compound 2, each with 2 dose groups, 10 mice in each group. Except for the normal control group, the mice were lightly anesthetized with ether and 15 LD 50Each mouse was inoculated with H1N1 / PR8 influenza virus droplets (30 μl). Administration began on the day of infection, with 0.2 ml / 10 g administered orally once daily for four consecutive days. A normal control group and a model control group were administered distilled water by gavage under the same conditions. On the fifth day, the mice were weighed and dissected, and lung weights were measured. Lung index and lung index inhibition rate were calculated. Results were statistically analyzed using the t-test for intergroup comparisons.

[0349] Lung index (%) = lung wet weight (g) × 100 / body weight (g)

[0350] 3 Test results

[0351] Table 12 The therapeutic effects of the compounds of the present invention on the pneumonia model of mice infected with influenza virus H1N1 / PR8 strain

[0352] Note: Compared with the normal group ## P<0.01; compared with the model control group, ** P<0.01, * P<0.05

[0353] The results in Table 12 show that after mice were infected with influenza A (H1N1 / PR8) virus, the lung index of mice increased significantly, which was significantly different from that of the normal control group (P<0.01). After 4 days of treatment with compound 9, compound 12, and compound 2 starting from the day of infection, the lung index decreased significantly, which was significantly different from that of the model control group (P<0.01).

[0354] Table 13 The therapeutic effects of the compounds of the present invention on the pneumonia model of mice infected with influenza virus H1N1 / FM1 strain

[0355] Note: Compared with the normal group ## P<0.01; compared with the model control group, ** P<0.01, * P<0.05

[0356] The results in Table 13 show that after mice were infected with influenza A (H1N1 / FM1) virus, the lung index of mice increased significantly, which was significantly different from that of the normal control group (P<0.01). After 4 days of treatment with compound 9, compound 12, and compound 2 starting on the day of infection, the lung index decreased significantly, which was significantly different from that of the model control group (P<0.01).

[0357] Example 26: Therapeutic effect of compound 12 on the pneumonia model of mice infected with human coronavirus 229E

[0358] The experimental materials and experimental methods are the same as Example 23.

[0359] Table 14 Effects of compound 12 on the pneumonia model of mice infected with human coronavirus 229E

[0360] Note: Compared with the normal control group # P<0.05; compared with the model control group * P<0.05

[0361] The results in Table 14 show that after mice were infected with human coronavirus 229E, the lung index of mice in the model control group increased significantly, which was significantly different from that in the normal control group (P<0.05); the lung index of mice in the 15 mg / kg / d and 7.5 mg / kg / d dose groups of compound 12 decreased significantly, which was significantly different from that in the model control group (P<0.01, P<0.05).

[0362] Example 27: Acute toxicity test of compound 4 in mice

[0363] 1. Test methods

[0364] Seventy ICR mice, weighing 17-21 g, were randomly divided into seven groups based on fasting body weight: a normal control group and six groups of 10 mice (half male and half female) receiving the test drug (Compound 4) at doses of 475, 633, 844, 1125, 1500, and 2000 mg / kg. After a 15-hour fast, each group received a single oral gavage of 40 ml / kg. The control group received an equal volume of 0.5% sodium carboxymethylcellulose solution once daily. The animals were observed for mortality for 14 days after administration.

[0365] Immediately after administration, observe the animals for signs of toxicity, the severity of toxicity, the time of onset and disappearance of toxicity, record adverse reactions, and perform a gross autopsy on dead animals, including observation of the animal's fur, eyes, ears, mouth, nose, genital pore, anus, and its mucous membranes.

[0366] 2. Experimental Results

[0367] 2.1 Observation of mouse mortality and adverse reactions

[0368] Compound 4 was administered to animals at doses of 475, 633, 844, 1125, 1500, and 2000 mg / kg, once a day by oral gavage. The main toxic reaction observed was acute death.

[0369] Animal deaths occurred in groups receiving 1125 mg / kg or higher of the test article, but none occurred in groups receiving 844 mg / kg or lower. All deaths occurred within 4 days of dosing, with the peak mortality occurring between 24 and 48 hours after dosing. The mortality rates for the six dose groups were 0%, 0%, 0%, 20%, 80%, and 100%, respectively.

[0370] 2.2 Aside from acute mortality, other macroscopically observed adverse reactions primarily included decreased spontaneous activity, recumbency, ataxia, tremor, convulsions, proneness, loss of righting reflex, and piloerection. These changes occurred to varying degrees in the 633, 844, 1125, 1500, and 2000 mg / kg test article groups, with incidences of 40%, 60%, 80%, 100%, and 100%, respectively, occurring within 60 minutes to 5 days after administration. No macroscopically observed adverse reactions were observed in the 475 mg / kg test article group. Thereafter, until the end of the 14-day observation period, no abnormalities were observed in the animals' general condition, activity, gait, respiration, feeding, drinking, bowel movements, and fur.

[0371] In summary: LD was calculated using the Bliss method 50 The maximum nonlethal dose was 844 mg of test sample / kg; the maximum no-adverse-effect dose was 475 mg of test sample / kg.

[0372] Example 28: Acute toxicity test of compound 12 in mice

[0373] 1. Test methods

[0374] Thirty ICR mice, weighing 17-21 g, were randomly divided into three groups based on fasting body weight: a normal control group and groups receiving either 2000 mg or 4000 mg of the test drug (Compound 12) per kg, with 10 mice in each group, half male and half female. After fasting for approximately 15 hours, each group received a single oral gavage of 40 ml / kg. The control group received an equal volume of 0.5% sodium carboxymethylcellulose solution once daily. Animals were observed for mortality for 14 days after administration.

[0375] Immediately after administration, observe the animals for signs of toxicity, the severity of toxicity, the time of onset and disappearance of toxicity, record adverse reactions, and perform a gross autopsy on dead animals, including observation of the animal's fur, eyes, ears, mouth, nose, genital pore, anus, and its mucous membranes.

[0376] 2. Experimental Results

[0377] Compound 12 was administered to animals by gavage once daily at doses of 2000 and 4000 mg / kg. The animals were observed immediately after administration and for the entire 14-day observation period. No abnormalities were observed in their general condition, activity, gait, respiration, feeding, drinking, bowel movements, or fur. No animals died during the experiment.

[0378] In combination with the above examples, regarding the therapeutic effects of the compounds of the present invention on the pneumonia model of mice infected with influenza virus H1N1 / FM1 strain and the effects on the pneumonia model of mice infected with human coronavirus 229E, compound 4 has a stronger efficacy than the modified precursor 7-hydroxyisoflavone, and the efficacy of 7-hydroxyisoflavone is not very strong, indicating that the 7-position modification strategy of 7-hydroxyisoflavone of the present invention has a very important influence on the antiviral efficacy of such isoflavone derivatives; and compound 4 has a stronger efficacy than compound F2 (7-position glycosylation strategy derivative), compound F4 (7-position alkoxyalkoxy derivative), and compound F5 (7-position amide alkoxy derivative), indicating that the antiviral effect of compound 4 obtained by the modification strategy of the cycloalkylaminoalkoxy strategy is better. Compound 4 has a stronger antiviral efficacy than both compound 5 and compound 7, indicating that the derivative with the 7-position 2-(cyclopropylamino)ethoxy substituent is more effective. This indicates that the position and structure of the substituents have a significant impact on the antiviral efficacy of 7-hydroxyisoflavone derivatives, and experiments have shown that the antiviral efficacy of the 2-(cyclopropylamino)ethoxy substituent introduced at the 7-position is the best. Compounds 9 and 12 derived from compound 4 also have strong efficacy, but compounds 10 and 11 derived from compound 4 have poor efficacy, indicating that the structure of the cyclopropyl group and R6 in general formula (I) has a significant impact on the antiviral efficacy. While retaining the cyclopropylamino substituent, derivatives in which R6 is an alkyl group or a substituted alkyl group have strong pharmacological activity. At the same time, the results of previous toxicological studies showed that the LD50 of compound 4 in the acute toxicity test in mice was 1299.054 mg, and the maximum concentration of compound 12 that can be administered orally is 4000 mg / kg, with no animal deaths. This indicates that compound 12 has a larger safety window and better efficacy than compound 4, indicating that derivatives in which R6 is an alkyl group or a substituted alkyl group not only maintain better pharmacological activity but also have higher safety.

[0379] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt, solvate, optically pure isomer, stereoisomer or mixture thereof, X1 and X2 are each independently selected from the following group: O, NR7; wherein, The R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, cycloalkyl, and substituted cycloalkyl; X3 is selected from the following group: O, NR8; wherein, R8 is selected from the following group: hydrogen, alkyl; R 1a 、R 1b 、R 1c Each independently selected from the group consisting of hydrogen, hydroxy, and alkoxy; R2 is selected from the group consisting of substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3a 、R 3b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen; R 4a 、R 4b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen; R5 is selected from the group consisting of hydrogen or alkoxy; R6 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C2-C6 acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted carbamoyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; wherein R7 is selected from the group consisting of C2-C6 acyl, C2-C6 amide, aryl, heteroaryl, cycloalkyl, heterocyclyl, NR8COR9; wherein R8 is selected from the group consisting of hydrogen, alkyl; and R9 is selected from the group consisting of alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl. Ring A is a substituted or unsubstituted cycloalkyl group; n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Wherein, each substitution refers to the replacement of hydrogen atoms on the group by one or more substituents selected from the group consisting of cyano, halogen, alkyl, hydroxy, alkoxy, alkenyl, alkynyl, aryl, and heteroaryl; Furthermore, the compound of formula I does not include In the above formulas, unless otherwise specified, the alkyl group is a C1-C6 alkyl group, and the aryl group is a C6-C 10 The aryl group is a C3-C8 cycloalkyl group, the alkoxy group is a C1-C6 alkoxy group, the alkenyl group is a C2-C6 alkenyl group, the alkynyl group is a C2-C6 alkynyl group, and the heteroaryl group is a 5-12 membered (preferably 5-7 membered) heteroaryl group.

2. The compound according to claim 1, wherein X1 is 0; and / or X2 is O. In another preferred embodiment, the R7 is selected from the following group: hydrogen and alkyl. In another preferred embodiment, X3 is O. In another preferred embodiment, R 1a 、R 1b 、R 1c are each independently selected from hydrogen.

3. The compound according to claim 1, wherein R2 is a substituted or unsubstituted aryl group, preferably a substituted or unsubstituted phenyl group. In another preferred embodiment, R 3a 、R 3b Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, and halogen. In another preferred embodiment, R 4a 、R 4b Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, and halogen. In another preferred embodiment, R5 is selected from the following group: hydrogen or C1-C4 alkoxy. In another preferred embodiment, R6 is selected from the following groups: hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted C2-C6 acyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; R7 is selected from the following group: C2-C6 acyl, C2-C6 amide, aryl, NR8COR9, and R8 is selected from the following group: hydrogen, alkyl; R9 is selected from the following group: alkyl, aryl. In another preferred embodiment, ring A is a substituted or unsubstituted C3-C7 cycloalkyl group, preferably a C3-C6 cycloalkyl group. In another preferred embodiment, n is 1, 2, 3 or 4. In another preferred embodiment, the R6 is selected from the following group: hydrogen, substituted or unsubstituted alkyl. In another preferred embodiment, said R6 is selected from the following group: hydrogen, unsubstituted alkyl.

4. The compound according to claim 1, wherein The compound of formula I has the structure shown in formula II, R 9a 、R 9b 、R 9c Each is independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C 10 Aryl, 5-12 membered heteroaryl; R 10a 、R 10b 、R 10c 、R 10d 、R 10e Each is independently selected from the group consisting of hydrogen, hydroxy, C1-C6 alkoxy, halogen, and cyano; m is 1, 2, 3, 4 or 5.

5. The compound according to claim 4, characterized in that The compound of formula II is selected from the following group:

6. The compound according to claim 1, wherein The compound of formula I has the structure shown in formula III, R 11a 、R 11b 、R 11c Each is independently selected from the group consisting of hydrogen, hydroxy, halogen, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C 10 Aryl, 5-12 membered heteroaryl; R 12 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C2-C6 acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted carbamoyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; wherein R7 is selected from the group consisting of C2-C6 acyl, C2-C6 amide, aryl, heteroaryl, cycloalkyl, heterocyclyl, NR8COR9; wherein R8 is selected from the group consisting of hydrogen, alkyl; and R9 is selected from the group consisting of alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl. R 13a 、R 13b 、R 13c 、R 13d 、R 13e Each is independently selected from the group consisting of hydrogen, hydroxy, alkoxy, halogen, and cyano.

7. The compound according to claim 6, characterized in that The compound of formula III is selected from the following group:

8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt, solvate, optically pure isomer or stereoisomer thereof; and a pharmaceutically acceptable carrier.

9. Use of the compound of formula I, or its pharmaceutically acceptable salt, solvate, optically pure isomer, stereoisomer or mixture thereof, or the pharmaceutical composition of claim 8, characterized in that: for preparing a pharmaceutical composition; X1 and X2 are each independently selected from the group consisting of O and NR7; wherein R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, cycloalkyl, and substituted cycloalkyl; X3 is selected from the following group: O, NR8; wherein, R8 is selected from the following group: hydrogen, alkyl; R 1a 、R 1b 、R 1c Each independently selected from the group consisting of hydrogen, hydroxy, and alkoxy; R2 is selected from the group consisting of substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3a 、R 3b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen; R 4a 、R 4b Each is independently selected from the group consisting of hydrogen, alkyl, and halogen; R5 is selected from the group consisting of hydrogen or alkoxy; R6 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, aminoalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C2-C6 acyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted carbamoyl, or (CH2) t R7; wherein t is 1, 2, 3, 4, 5 or 6; wherein R7 is selected from the group consisting of C2-C6 acyl, C2-C6 amide, aryl, heteroaryl, cycloalkyl, heterocyclyl, NR8COR9; wherein R8 is selected from the group consisting of hydrogen, alkyl; and R9 is selected from the group consisting of alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl. Ring A is a substituted or unsubstituted cycloalkyl group; n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Wherein, each substitution refers to the replacement of hydrogen atoms on the group by one or more substituents selected from the group consisting of cyano, halogen, alkyl, hydroxy, alkoxy, alkenyl, alkynyl, aryl, and heteroaryl; The pharmaceutical composition is used for a purpose selected from the group consisting of: (1) Improve, alleviate or reverse diseases or symptoms caused by viral infection; (2) As a SARS-Cov-2 virus ACE-2 receptor antagonist; (3) As an inhibitor of inflammatory cytokines after infection.

10. The use according to claim 9, characterized in that The virus is selected from the group consisting of influenza virus, respiratory syncytial virus, coronavirus (such as SARS-COV-2 virus), and parainfluenza virus. In another preferred embodiment, the infection is a viral infection. In another preferred embodiment, the virus is selected from the following group: influenza virus, respiratory syncytial virus, coronavirus (such as SARS-COV-2 virus), and parainfluenza virus.